Latest Crohn's disease Stories
Presentations examine certain demographic and clinical disease characteristics that may be indicative of Cimzia® treatment response and remission for moderate to severe Crohn's disease ATLANTA,
Immune Pharmaceuticals Recently Initiated Phase II Clinical Trial in Ulcerative Colitis CAMBRIDGE, Mass. and HERZLIYA PITUACH, Israel, Oct.
Regarded as one of the world's leading experts in the field of pediatric inflammatory bowel disease (IBD), Marla Dubinsky, MD, has been appointed Chief of Pediatric Gastroenterology in the
SAN DIEGO, Sept. 25, 2014 /PRNewswire/ -- Meritage Pharma, Inc.
-- HUMIRA is now indicated to treat pediatric patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators
Company Recently Initiated Phase II in Bullous Pemphigoid CAMBRIDGE, Mass. and HERZLIYA PITUACH, Israel, Sept. 18, 2014 /PRNewswire/ -- Immune Pharmaceuticals Inc.
Genetic changes that occur in patients with the bowel condition Crohn's disease could hold clues to fighting the illness.
At Weinberg Gastrointestinal, patients can now receive both American and Canadian screening colonoscopies in Gilbert, Arizona GILBERT, Ariz., Aug.
- The act of sweetening by admixture of some saccharine substance.